Gwenaëlle Jacq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gwenaëlle Jacq has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Stephane Legriel
Médecine Intensive Réanimation, Centre Hospitalier de Versailles - Site André Mignot, 177 rue de Versailles, Le Chesnay cedex, 78150, France; IctalGroup, Le Chesnay, France; Université Paris-Saclay, Université de Versailles Saint Quentin enYvelines, Villejuif, 94807, France
8 shared publications Stéphane Legriel
7 shared publications- Jonathan Chelly
CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France
4 shared publications Stephane Legriel
Intensive Care Department, GHT Sud Yvelines, Centre Hospitalier de Versailles - Site André Mignot, Le Chesnay Cedex, France
4 shared publications- Jean-Baptiste Lascarrou
CHU Nantes
3 shared publications Olivier Lesieur
IctalGroup, Le Chesnay, France
3 shared publications
Latest Publications
- 9 November 2026
- Published by Elsevier in Intensive and Critical Care Nursing
- Vol. 99
Health-related quality of life after intensive care: a longitudinal cohort study using item-level network analysis
- 9 November 2026
- Published by Elsevier in Intensive and Critical Care Nursing
- Vol. 99
Health-related quality of life after intensive care: a longitudinal cohort study using item-level network analysis
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218544
Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus
Background and ObjectivesStatus epilepticus (SE) is a critical neurologic emergency requiring prompt symptomatic and etiologic treatment. However, the diagnostic yield of etiologic investigations r...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218544
Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus
Background and ObjectivesStatus epilepticus (SE) is a critical neurologic emergency requiring prompt symptomatic and etiologic treatment. However, the diagnostic yield of etiologic investigations r...
- Open Access
- 4 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Post-traumatic stress disorder in nursing students on the frontline during the first Covid-19 wave: a cross-sectional survey
- 4 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPost-traumatic stress disorder in nursing students on the frontline during the first Covid-19 wave: a cross-sectional survey
- 17 April 2026
- Published by Elsevier in Australian Critical Care
- Vol. 39 (3) , 101581
Efficacy of local cryoanalgesia by vapocoolant spray on pain induced by arterial puncture in critically ill patients: A multicentre randomised controlled trial (SNOW study)
- 17 April 2026
- Published by Elsevier in Australian Critical Care
- Vol. 39 (3) , 101581
Efficacy of local cryoanalgesia by vapocoolant spray on pain induced by arterial puncture in critically ill patients: A multicentre randomised controlled trial (SNOW study)
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Évaluation des résultats cliniques après un état de mal épileptique de l’adulte requérant une prise en charge en réanimation
Les états de mal épileptiques (EME) chez l’adulte constituent une urgence neurologique absolue. Alors que la description et la recherche de marqueurs associés à la morbidité ont fait l’objet d’une attention particulière dans la littérature, essentiellement à l’aide de scores génériques tels que le score Glasgow Outcome Scale (GOS) ou le score modified Rankin Scale (mRS), la description précise des conséquences de ces atteintes fonctionnelles et de leur retentissement en termes de qualité de vie, et de critères rapportés par le patient lui-même après un EME n’a été que très peu étudiée.L’objectif de ce travail de thèse était de décrire et enrichir la compréhension du pronostic fonctionnel chez les patients après un EME ayant requis une prise en charge en réanimation en s’appuyant sur le cadre structuré des Clinical Outcome Assessments (COAs) se déclinant en 4 categories; (1) Clinician-reported outcome (ClinROs), (2) Observer-reported outcome (ObsROs), (3) Performance outcome (PerfOs) et (4) Patient-reported outcome (PROs). Le 1r travail a consisté en une analyse post-hoc des données issues de l’essai contrôlé randomisé HYBERNATUS. Les patients ont ainsi pu être vus en consultation à J90 afin d’explorer divers domaines en associant trois ClinROs. Sur les 229 patients ayant obtenu un score GOS ≥ 3 à J90 (58,2 % d'hommes, âge médian de 56 ans [47-67]), 67 (29 %) ont consulté un neurologue en personne. Vingt-neuf patients (43 %) avaient des antécédents d'épilepsie et 16 (24 %) avaient subi une lésion cérébrale primaire. L’EMEC était réfractaire chez 22 patients (33 %). A J 90 après l'apparition de l’EMEC, les scores FIM (Functionnal Independence Measure) et MMSE (Mini Mental Stes Examination) médians étaient respectivement de 121 (112-125) et 26,0 (24,0-28,8). Le score GOS était de 3 chez 16 patients (33,8 %), de 4 chez 9 patients (13,4 %) et de 5 chez 42 patients (62,7 %). Les scores GOS les plus faibles étaient significativement associés à des scores FIM et MMSE plus faibles. Notre 2-ème de travail a consisté en la réalisation d’une revue systématique sur l’utilisation des PROs après un EME. Notre revue a ainsi mis en évidence une littérature pauvre sur les PROs. Seules 3 études ont été identifiées, avec de faibles effectifs, dont deux étaient rétrospectives. Les principaux domaines investigués concernaient principalement la qualité de vie _ (QVLS) et la santé mentale , tous deux étaient altérées. Les scores de QVLS variaient de 41,7 ± 11,5 à 48,3 ± 24,5. La prévalence de la dépression variait de 30 % à 36 %, tandis que celle de l’anxiété allait de 22 % à 62 %. Ces résultats suggéraient une diminution de la QVLS. Enfin dans notre 3-ème et dernier travail nous avons réalisé une étude transversale agrégant les données prospectives du registre ICTAL des états de mal épileptiques avec la mesure de ClinROs, PerfOs et PROs issues de la passation de questionnaires couvrant différents domaines, comme la récupération fonctionnelle, la QVLS, le statut cognitif, la dépendance, la santé mentale et de soutien social. L'âge médian des 66 répondants était de 58 [47, 68] ans et 43 patients (65,2 %) étaient des hommes. Au total, 15 patients (22,7 %) avaient des antécédents d'épilepsie. Dans l'ensemble, 48 patients (70,7 %) de notre cohorte présentaient une QVLS moins bonne que la population de référence. Les scores composites physiques et mentaux du SF36 ont montré des altérations similaires, avec des valeurs moyennes de 42,1 (11,1) et 42,3 (12,5), respectivement. Une corrélation forte et significative a été identifiée entre le score total du questionnaire SF-36 et les domaines de la dépendance et de la santé mentale. La recherche d'une association entre les prédicteurs d'une issue défavorable après EME et les résultats de la QVLS au moment de l'évaluation transversale chez les patients ayant un score SF-36 inférieur à celui de la population de référence s'est révélée négative pour toutes les variables testées.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Évaluation des résultats cliniques après un état de mal épileptique de l’adulte requérant une prise en charge en réanimation
Les états de mal épileptiques (EME) chez l’adulte constituent une urgence neurologique absolue. Alors que la description et la recherche de marqueurs associés à la morbidité ont fait l’objet d’une attention particulière dans la littérature, essentiellement à l’aide de scores génériques tels que le score Glasgow Outcome Scale (GOS) ou le score modified Rankin Scale (mRS), la description précise des conséquences de ces atteintes fonctionnelles et de leur retentissement en termes de qualité de vie, et de critères rapportés par le patient lui-même après un EME n’a été que très peu étudiée.L’objectif de ce travail de thèse était de décrire et enrichir la compréhension du pronostic fonctionnel chez les patients après un EME ayant requis une prise en charge en réanimation en s’appuyant sur le cadre structuré des Clinical Outcome Assessments (COAs) se déclinant en 4 categories; (1) Clinician-reported outcome (ClinROs), (2) Observer-reported outcome (ObsROs), (3) Performance outcome (PerfOs) et (4) Patient-reported outcome (PROs). Le 1r travail a consisté en une analyse post-hoc des données issues de l’essai contrôlé randomisé HYBERNATUS. Les patients ont ainsi pu être vus en consultation à J90 afin d’explorer divers domaines en associant trois ClinROs. Sur les 229 patients ayant obtenu un score GOS ≥ 3 à J90 (58,2 % d'hommes, âge médian de 56 ans [47-67]), 67 (29 %) ont consulté un neurologue en personne. Vingt-neuf patients (43 %) avaient des antécédents d'épilepsie et 16 (24 %) avaient subi une lésion cérébrale primaire. L’EMEC était réfractaire chez 22 patients (33 %). A J 90 après l'apparition de l’EMEC, les scores FIM (Functionnal Independence Measure) et MMSE (Mini Mental Stes Examination) médians étaient respectivement de 121 (112-125) et 26,0 (24,0-28,8). Le score GOS était de 3 chez 16 patients (33,8 %), de 4 chez 9 patients (13,4 %) et de 5 chez 42 patients (62,7 %). Les scores GOS les plus faibles étaient significativement associés à des scores FIM et MMSE plus faibles. Notre 2-ème de travail a consisté en la réalisation d’une revue systématique sur l’utilisation des PROs après un EME. Notre revue a ainsi mis en évidence une littérature pauvre sur les PROs. Seules 3 études ont été identifiées, avec de faibles effectifs, dont deux étaient rétrospectives. Les principaux domaines investigués concernaient principalement la qualité de vie _ (QVLS) et la santé mentale , tous deux étaient altérées. Les scores de QVLS variaient de 41,7 ± 11,5 à 48,3 ± 24,5. La prévalence de la dépression variait de 30 % à 36 %, tandis que celle de l’anxiété allait de 22 % à 62 %. Ces résultats suggéraient une diminution de la QVLS. Enfin dans notre 3-ème et dernier travail nous avons réalisé une étude transversale agrégant les données prospectives du registre ICTAL des états de mal épileptiques avec la mesure de ClinROs, PerfOs et PROs issues de la passation de questionnaires couvrant différents domaines, comme la récupération fonctionnelle, la QVLS, le statut cognitif, la dépendance, la santé mentale et de soutien social. L'âge médian des 66 répondants était de 58 [47, 68] ans et 43 patients (65,2 %) étaient des hommes. Au total, 15 patients (22,7 %) avaient des antécédents d'épilepsie. Dans l'ensemble, 48 patients (70,7 %) de notre cohorte présentaient une QVLS moins bonne que la population de référence. Les scores composites physiques et mentaux du SF36 ont montré des altérations similaires, avec des valeurs moyennes de 42,1 (11,1) et 42,3 (12,5), respectivement. Une corrélation forte et significative a été identifiée entre le score total du questionnaire SF-36 et les domaines de la dépendance et de la santé mentale. La recherche d'une association entre les prédicteurs d'une issue défavorable après EME et les résultats de la QVLS au moment de l'évaluation transversale chez les patients ayant un score SF-36 inférieur à celui de la population de référence s'est révélée négative pour toutes les variables testées.
- Open Access
Assessment of health-related quality of life, cognitive, physical and psychological impairments in critically ill adults after status epilepticus (POSEIDON 2): protocol for a multicentre longitudinal study
Introduction Status epilepticus (SE) in adults is a serious neurological emergency that can lead to high morbidity and mortality rates. Although functional outcomes are often assessed using general scoring systems, limited data on health-related quality of life (HRQoL) in patients admitted to intensive care units (ICUs) are still limited. Furthermore, comprehensive evaluations of patient-reported physical, cognitive, mental health and psychological outcomes are lacking in this population. POSEIDON 2 aims to assess HRQoL and cognitive, physical and psychological impairments at 3 and 12 months after ICU discharge following SE and quantify caregiver burden. Methods and analysis POSEIDON 2 is a prospective, multicentre, longitudinal study conducted in 19 French ICUs. The study combines data from the SE ICTAL Registry with data from patients who survived admission to the ICU for SE, who will be recruited for the study. The study also includes patient-reported outcome (PRO) data collected 3 (M3) and 12 (M12) months after discharge from the ICU using validated instruments. The Zarit scale will be used to measure the burden on caregivers at M3 and M12. The primary endpoint is the prevalence of overall HRQOL impairment at M3 and M12, as defined by dichotomous scores on the physical and mental components of the 36-Item Short Form Health Survey compared with those of the general population. Secondary endpoints include domain-specific impairments, such as cognitive function, dependence, mental health and patient experiences. The sample size has been calculated based on an estimated prevalence of 75% for HRQoL impairment, with a planned sample size of 140 patients. Ethics and dissemination The POSEIDON 2 study protocol received ethical approval from the ethics committee ‘Comité de Protection des Personnes Ouest VI’ on 5 October 2023 (#2023-A01223-42). The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice and the regulatory requirements of France. Written informed consent is obtained from participants, who are able to decline participation or withdraw from the study at any time. Findings will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences. Trial registration number NCT06100978.
Open AccessAssessment of health-related quality of life, cognitive, physical and psychological impairments in critically ill adults after status epilepticus (POSEIDON 2): protocol for a multicentre longitudinal study
Introduction Status epilepticus (SE) in adults is a serious neurological emergency that can lead to high morbidity and mortality rates. Although functional outcomes are often assessed using general scoring systems, limited data on health-related quality of life (HRQoL) in patients admitted to intensive care units (ICUs) are still limited. Furthermore, comprehensive evaluations of patient-reported physical, cognitive, mental health and psychological outcomes are lacking in this population. POSEIDON 2 aims to assess HRQoL and cognitive, physical and psychological impairments at 3 and 12 months after ICU discharge following SE and quantify caregiver burden. Methods and analysis POSEIDON 2 is a prospective, multicentre, longitudinal study conducted in 19 French ICUs. The study combines data from the SE ICTAL Registry with data from patients who survived admission to the ICU for SE, who will be recruited for the study. The study also includes patient-reported outcome (PRO) data collected 3 (M3) and 12 (M12) months after discharge from the ICU using validated instruments. The Zarit scale will be used to measure the burden on caregivers at M3 and M12. The primary endpoint is the prevalence of overall HRQOL impairment at M3 and M12, as defined by dichotomous scores on the physical and mental components of the 36-Item Short Form Health Survey compared with those of the general population. Secondary endpoints include domain-specific impairments, such as cognitive function, dependence, mental health and patient experiences. The sample size has been calculated based on an estimated prevalence of 75% for HRQoL impairment, with a planned sample size of 140 patients. Ethics and dissemination The POSEIDON 2 study protocol received ethical approval from the ethics committee ‘Comité de Protection des Personnes Ouest VI’ on 5 October 2023 (#2023-A01223-42). The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice and the regulatory requirements of France. Written informed consent is obtained from participants, who are able to decline participation or withdraw from the study at any time. Findings will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences. Trial registration number NCT06100978.
- 28 October 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173, 110795
Health-Related quality of life after status epilepticus: A cross-sectional study from the ICTAL registry
- 28 October 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 173, 110795
Health-Related quality of life after status epilepticus: A cross-sectional study from the ICTAL registry
- 5 January 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 151, 109610
Patient-reported outcomes in adults after status epilepticus: A systematic review
- 5 January 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 151, 109610
Patient-reported outcomes in adults after status epilepticus: A systematic review
- 7 June 2023
- Published by Springer Nature in Neurocritical Care
- Vol. 40 (2) , 495-505
Clinician-Reported Physical and Cognitive Impairments After Convulsive Status Epilepticus: Post Hoc Study of a Randomized Controlled Trial
Background Clinician-reported outcome (ClinRO) measures are emerging as useful contributors to assessments of treatment benefits. The objective of this study was to collect ClinRO measures of physical and cognitive impairments after convulsive status epilepticus (CSE) requiring intensive care unit admission. Methods We conducted a post hoc analysis of the data from HYBERNATUS, a multicenter open-label controlled trial that randomized 270 critically ill patients with CSE requiring mechanical ventilation in 11 French intensive care units to therapeutic hypothermia (32–34 °C for 24 h) plus standard care or standard care alone. We included all patients who attended a day 90 in-person neurologist visit with measurement of the functional independence measure (FIM) score (range from 18 [total assistance] to 126 [total independence]), Mini-Mental State Examination (MMSE) score (range 0–30), and Glasgow outcome scale (GOS) score (1, death; 2, vegetative state; 3, severe disability; 4, moderate disability; and 5, mild or no disability). These three scores were compared across groups defined by several patient and CSE characteristics. Results Of 229 patients with GOS scores ≥ 3 on day 90 (male sex, 58.2%; median age, 56 years [47–67]), 67 (29%) attended an in-person neurologist visit. Twenty-nine (43%) patients had a previous history of epilepsy, and 16 (24%) patients had a primary brain insult. CSE was refractory in 22 (33%) patients. On day 90 after CSE onset, median FIM and MMSE scores were 121 (112–125) and 26.0 (24.0–28.8), respectively. The GOS score was 3 in 16 (33.8%) patients, 4 in 9 (13.4%) patients, and 5 in 42 (62.7%) patients. Worse GOS score values were significantly associated with worse FIM and MMSE scores. Conclusions In patients attending the in-person neurologist visit on day 90 after CSE onset, ClinRO measures indicated that the main impairments were cognitive. FIM and MMSE scores were associated with GOS scores. Further studies are needed to evaluate the possible impact of neuroprotective and rehabilitation strategies on disability and cognitive impairments in survivors of CSE. Clinical trial registration NCT01359332.
- 7 June 2023
- Published by Springer Nature in Neurocritical Care
- Vol. 40 (2) , 495-505
Clinician-Reported Physical and Cognitive Impairments After Convulsive Status Epilepticus: Post Hoc Study of a Randomized Controlled Trial
Background Clinician-reported outcome (ClinRO) measures are emerging as useful contributors to assessments of treatment benefits. The objective of this study was to collect ClinRO measures of physical and cognitive impairments after convulsive status epilepticus (CSE) requiring intensive care unit admission. Methods We conducted a post hoc analysis of the data from HYBERNATUS, a multicenter open-label controlled trial that randomized 270 critically ill patients with CSE requiring mechanical ventilation in 11 French intensive care units to therapeutic hypothermia (32–34 °C for 24 h) plus standard care or standard care alone. We included all patients who attended a day 90 in-person neurologist visit with measurement of the functional independence measure (FIM) score (range from 18 [total assistance] to 126 [total independence]), Mini-Mental State Examination (MMSE) score (range 0–30), and Glasgow outcome scale (GOS) score (1, death; 2, vegetative state; 3, severe disability; 4, moderate disability; and 5, mild or no disability). These three scores were compared across groups defined by several patient and CSE characteristics. Results Of 229 patients with GOS scores ≥ 3 on day 90 (male sex, 58.2%; median age, 56 years [47–67]), 67 (29%) attended an in-person neurologist visit. Twenty-nine (43%) patients had a previous history of epilepsy, and 16 (24%) patients had a primary brain insult. CSE was refractory in 22 (33%) patients. On day 90 after CSE onset, median FIM and MMSE scores were 121 (112–125) and 26.0 (24.0–28.8), respectively. The GOS score was 3 in 16 (33.8%) patients, 4 in 9 (13.4%) patients, and 5 in 42 (62.7%) patients. Worse GOS score values were significantly associated with worse FIM and MMSE scores. Conclusions In patients attending the in-person neurologist visit on day 90 after CSE onset, ClinRO measures indicated that the main impairments were cognitive. FIM and MMSE scores were associated with GOS scores. Further studies are needed to evaluate the possible impact of neuroprotective and rehabilitation strategies on disability and cognitive impairments in survivors of CSE. Clinical trial registration NCT01359332.
- 30 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (22) , E2247-E2258
Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma
Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472
- 30 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (22) , E2247-E2258
Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma
Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472